Maijie Life raises tens of millions of yuan in Series B for regenerative materials
What's the deal? Maijie Life ScienceDealroom has a profile for this one. Try Dealroom → has raised tens of millions of yuan in a Series B round, announced in June 2026. The round was backed by Shenzhen Industrial Investment and Jinyu MaowuDealroom has a profile for this one. Try Dealroom →.
What does the company do? Maijie develops regenerative repair materials for orthopaedics, sports medicine, dentistry, and medical aesthetics. It builds on two technology platforms: natural porous hydroxyapatite and cross-linked medical collagen.
What's the endgame? The company positions its Class III medical devices as higher-biocompatibility repair and filling materials. It aims to offer a closed-loop, full-chain solution spanning both serious medicine and consumer medicine.
Why now? Maijie closed a Series A of tens of millions of yuan in 2024, funded solely by the Huaxi Yuanyou fund, to support product innovation and clinical research. This Series B brings in a regional industrial investment platform alongside a market-driven institution.
The signal: The mix of investors — a state-linked platform plus a commercial firm — points to a bet on manufacturing capacity and regional industrial clusters rather than an early-stage concept play. It echoes a wider funding and expansion wave among Chinese regenerative and biomedical materials firms, backed by policy pushing high-end devices and domestic substitution.
Read more: ITJuzi
Image credit: SFU - Communications & Marketing
